Lexicon Pharma (LXRX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.50 +2.74%
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $15.86 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- CS Disco, Inc (LAW) Misses Q3 EPS by 6c; offers guidance
- Reynolds Consumer Products Inc. (REYN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
